Sofosbuvir & Velpatasvir:
Sofosbuvir and Velpatasvir are directly acting antiviral agents (DAA’s) which are involved in the treatment of chronic hepatitis C viral infection
Sofosbuvir and Velpatasvir are non-structural proteins like 5B & 5A which are fundamental drivers for hepatitis C virus multiplication
Both sofosbuvir and Velpatasvir have efficient anti-viral activity in contrast to the six most extensive HCV genotypes I to VI
Sofosbuvir and Velpatasvir is either used alone or in decompensated condition, these anti-viral components must be combined with ribavirin
However, sofosbuvir and Velpatasvir is considered as DAA and it is first single tablet drugs to prevent HCV infection caused by genotypes.
Various brands available: